Corcept Therapeutics Stock Forecast, Price & News

+0.41 (+1.87 %)
(As of 06/23/2021 12:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume8,885 shs
Average Volume582,073 shs
Market Capitalization$2.61 billion
P/E Ratio28.68
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CORT News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Corcept Therapeutics logo

About Corcept Therapeutics

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.81 out of 5 stars

Medical Sector

196th out of 2,105 stocks

Pharmaceutical Preparations Industry

92nd out of 832 stocks

Analyst Opinion: 1.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions

Is Corcept Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Corcept Therapeutics stock.
View analyst ratings for Corcept Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Corcept Therapeutics?

Wall Street analysts have given Corcept Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Corcept Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Corcept Therapeutics' next earnings date?

Corcept Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Corcept Therapeutics

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported $0.18 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.21 by $0.03. The biotechnology company had revenue of $79.44 million for the quarter, compared to the consensus estimate of $96.99 million. Corcept Therapeutics had a trailing twelve-month return on equity of 20.11% and a net margin of 29.23%. The firm's revenue was down 14.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.34 EPS.
View Corcept Therapeutics' earnings history

How has Corcept Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Corcept Therapeutics' stock was trading at $10.95 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CORT stock has increased by 104.7% and is now trading at $22.41.
View which stocks have been most impacted by COVID-19

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics updated its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $355 million-$385 million, compared to the consensus revenue estimate of $396.20 million.

What price target have analysts set for CORT?

3 brokerages have issued 12-month target prices for Corcept Therapeutics' stock. Their forecasts range from $16.00 to $29.00. On average, they expect Corcept Therapeutics' stock price to reach $22.50 in the next year. This suggests a possible upside of 0.4% from the stock's current price.
View analysts' price targets for Corcept Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Corcept Therapeutics' key executives?

Corcept Therapeutics' management team includes the following people:
  • Dr. Joseph K. Belanoff, Co-Founder, Pres, CEO & Director (Age 64, Pay $1.52M)
  • Dr. Hazel Hunt, Chief Scientific Officer
  • Mr. Sean Maduck, Chief Commercial Officer (Age 44, Pay $688.54k)
  • Dr. Andreas Grauer M.D., Chief Medical Officer (Age 60, Pay $791.98k)
  • Mr. Gary Charles Robb, Chief Bus. Officer & Sec. (Age 58, Pay $795.62k)
  • Mr. Atabak Mokari, Chief Financial Officer (Age 44)
  • Mr. Joseph Douglas Lyon, Chief Accounting Officer (Age 42)
  • Dr. Christopher Shayne James M.D., Director of Investor Relations
  • Donald E. Laferle, Sr. VP

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics CEO Joseph K. Belanoff on Joseph K. Belanoff has an approval rating of 100% among Corcept Therapeutics' employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Corcept Therapeutics' key competitors?

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (13.87%), Renaissance Technologies LLC (7.52%), Ingalls & Snyder LLC (5.92%), Dimensional Fund Advisors LP (2.24%), Geode Capital Management LLC (1.52%) and Parallel Advisors LLC (1.33%). Company insiders that own Corcept Therapeutics stock include Daniel N Swisher Jr, G Leonard Baker Jr, G Leonard Baker, Jr, Gary Charles Robb, Joseph Douglas Lyon and Sean Maduck.
View institutional ownership trends for Corcept Therapeutics

Which major investors are selling Corcept Therapeutics stock?

CORT stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Ingalls & Snyder LLC, LSV Asset Management, D. E. Shaw & Co. Inc., Jupiter Asset Management Ltd., Voloridge Investment Management LLC, Goldman Sachs Group Inc., and Schroder Investment Management Group. Company insiders that have sold Corcept Therapeutics company stock in the last year include Daniel N Swisher Jr, Gary Charles Robb, Joseph Douglas Lyon, and Sean Maduck.
View insider buying and selling activity for Corcept Therapeutics
or view top insider-selling stocks.

Which major investors are buying Corcept Therapeutics stock?

CORT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Boston Trust Walden Corp, AJ Wealth Strategies LLC, Allianz Asset Management GmbH, TD Asset Management Inc., Geode Capital Management LLC, BI Asset Management Fondsmaeglerselskab A S, and Morgan Stanley. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr, and G Leonard Baker, Jr.
View insider buying and selling activity for Corcept Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Corcept Therapeutics?

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $22.41.

How much money does Corcept Therapeutics make?

Corcept Therapeutics has a market capitalization of $2.61 billion and generates $353.87 million in revenue each year. The biotechnology company earns $106.01 million in net income (profit) each year or $0.85 on an earnings per share basis.

How many employees does Corcept Therapeutics have?

Corcept Therapeutics employs 236 workers across the globe.

What is Corcept Therapeutics' official website?

The official website for Corcept Therapeutics is

Where are Corcept Therapeutics' headquarters?

Corcept Therapeutics is headquartered at 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.